Previous Close | 0.0150 |
Open | 0.0250 |
Bid | 0.0150 x N/A |
Ask | 0.0250 x N/A |
Day's Range | 0.0250 - 0.0250 |
52 Week Range | 0.0100 - 0.0400 |
Volume | |
Avg. Volume | 32,031 |
Market Cap | 1.978M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VANCOUVER, British Columbia, January 08, 2024--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.
VANCOUVER, British Columbia, December 07, 2023--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company’s lead clinical program, L-130, a proprietary stabilized psilocin conjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmaco
VANCOUVER, British Columbia, December 05, 2023--Lobe Sciences Reports 12 Months Stability for Lead Psilocin Drug Candidate (L-130).